HER2-positive Breast Cancer
Showing 1 - 25 of 200
HER2-positive Breast Cancer, Advanced Breast Cancer Trial in Phoenix, Miami, Boston (Prolonged Overnight Fasting,
Not yet recruiting
- HER2-positive Breast Cancer
- Advanced Breast Cancer
- Prolonged Overnight Fasting
- +2 more
-
Phoenix, Arizona
- +2 more
Nov 8, 2023
HER2-positive Breast Cancer Trial in Nanjing (HS022, Trastuzumab, Vinorelbine Bitartrate)
Completed
- HER2-positive Breast Cancer
- HS022
- +2 more
-
Nanjing, Jiangsu, ChinaJiangsu Province People's Hospital (First Affiliated Hospital of
Oct 25, 2023
ctDNA During Neoadjuvant Chemotherapy for Breast Cancer.
Recruiting
- Breast Cancer Female
- +4 more
-
Ho Chi Minh City, Vietnam
- +1 more
Oct 16, 2023
Breast Cancer, HER2-positive Breast Cancer Trial in São Paulo (PHESGO)
Not yet recruiting
- Breast Cancer
- HER2-positive Breast Cancer
-
São Paulo, BrazilCentro Paulista de Oncologia (Oncoclínicas)
Oct 3, 2023
Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2
Recruiting
- HER2-positive Breast Cancer
- Early-stage Breast Cancer
- pyrotinib combined with Capecitabine
- treatment of physician's choice
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Sep 6, 2023
HER2-positive Breast Cancer, LMD Trial (Tucatinib 150 MG, Trastuzumab, Capecitabine)
Not yet recruiting
- HER2-positive Breast Cancer
- LMD
- Tucatinib 150 MG
- +3 more
- (no location specified)
Aug 24, 2023
HER2-positive Breast Cancer Trial in China (TQB2440 injection + Trastuzumab + Docetaxel, Perjeta + Trastuzumab + Docetaxel)
Active, not recruiting
- HER2-positive Breast Cancer
- TQB2440 injection + Trastuzumab + Docetaxel
- Perjeta + Trastuzumab + Docetaxel
-
Chongqing, Chongqing, China
- +5 more
Aug 3, 2023
HER2-positive Breast Cancer Trial in Amsterdam (Trastuzumab deruxtecan)
Not yet recruiting
- HER2-positive Breast Cancer
- Trastuzumab deruxtecan
-
Amsterdam, NetherlandsAntoni van Leeuwenhoek
Aug 7, 2023
HER2-positive Breast Cancer Trial in Shanghai (68Ga/131I-SGMIB-5F7)
Not yet recruiting
- HER2-positive Breast Cancer
- 68Ga/131I-SGMIB-5F7
-
Shanghai, ChinaHuashan Hospital
Aug 1, 2023
HER2-positive Breast Cancer Trial (Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab))
Not yet recruiting
- HER2-positive Breast Cancer
- Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab)
- (no location specified)
Jul 20, 2023
Triple Negative Breast Cancer, HER2-positive Breast Cancer Trial in Seoul (exosome and ctDNA evaluation)
Active, not recruiting
- Triple Negative Breast Cancer
- HER2-positive Breast Cancer
- exosome and ctDNA evaluation
-
Seoul, Korea, Republic ofJi-Yeon Kim
Jul 13, 2023
Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer Trial in Amsterdam (89Zr-DFO*-trastuzumab PET scan)
Recruiting
- Breast Cancer
- +5 more
- 89Zr-DFO*-trastuzumab PET scan
-
Amsterdam, Noord-Holland, NetherlandsAmsterdamUMC
Jul 12, 2023
HER2-positive Breast Cancer Trial in Guanzhou (Eribulin mesylate injection?Pertuzumab?Trastuzumab)
Recruiting
- HER2-positive Breast Cancer
- Eribulin mesylate injection、Pertuzumab、Trastuzumab
-
Guanzhou, Guangdong, ChinaLI YuDong
Jul 13, 2023
Breast Cancer, HER2-positive Breast Cancer Trial in Zhengzhou (Albumin paclitaxel+trastuzumab+pyrrolitinib,
Active, not recruiting
- Breast Cancer
- HER2-positive Breast Cancer
- Albumin paclitaxel+trastuzumab+pyrrolitinib
- Docetaxel+Carboplatin+trastuzumab+Parstuzumab
-
Zhengzhou, Henan, ChinaHenan cancer hospital
Jun 23, 2023
Early On-treatment Transcriptional Profiling as Predictor of
Recruiting
- HER2-positive Breast Cancer
- +2 more
- Trastuzumab (neoadjuvant)
- +2 more
-
Hospitalet de Llobregat, Barcelona, SpainInstitut Català d'Oncologia l'Hospitalet
Jun 12, 2023
Cardiotoxicity, HER2-positive Breast Cancer, Heart Failure Trial in London (Phased withdrawal of heart failure medications)
Not yet recruiting
- Cardiotoxicity
- +3 more
- Phased withdrawal of heart failure medications
-
London, United Kingdom
- +1 more
May 19, 2023
HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer Trial in Chicago, Minneapolis (ALX148, Fam-Trastuzumab
Recruiting
- HER2-positive Breast Cancer
- +17 more
- ALX148
- Fam-Trastuzumab Deruxtecan-Nxki
-
Chicago, Illinois
- +1 more
May 19, 2023
HER2-positive Breast Cancer Trial in Nanjing (Pyrotinib)
Recruiting
- HER2-positive Breast Cancer
-
Nanjing, Jiangsu, ChinaJiangSu Province Hospital/ The First Affiliated Hospital of Nanj
Apr 26, 2023
Leptomeningeal Disease, Triple Negative Breast Cancer, HER2-positive Breast Cancer Trial in Tampa (Dendritic Cell Vaccine)
Recruiting
- Leptomeningeal Disease
- +2 more
- Dendritic Cell Vaccine
-
Tampa, FloridaMoffitt Cancer Center
Apr 11, 2023
Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer Trial in Boston (Trastuzumab
Not yet recruiting
- Invasive Breast Cancer
- +4 more
- Trastuzumab deruxtecan
- Durvalumab
-
Boston, Massachusetts
- +1 more
Mar 20, 2023
Patterns and Associated Outcomes in Patients of China With
Not yet recruiting
- HER2-positive Breast Cancer
- Electronic medical record and hospital information system or other available resources
-
Beijing, China
- +6 more
Mar 3, 2023
Early-stage Breast Cancer, HER2-positive Breast Cancer, Adjuvant Treatment After Trastuzumab Trial in Guangzhou (Trastuzumab and
Recruiting
- Early-stage Breast Cancer
- +4 more
- Trastuzumab and nelatinib
- Trastuzumab and Parstuzumab
-
Guangzhou, ChinaSun Yat-sen University Sun Yat-sen Memorial Hospital
Mar 12, 2023
HER2-positive Breast Cancer Trial in Rome (PIK3CA analysis)
Active, not recruiting
- HER2-positive Breast Cancer
- PIK3CA analysis
-
Rome, RM, ItalyFondazione Policlinico Universitario Agostino Gemelli IRCCS
Feb 20, 2023
Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer Trial in Boston (Cessation of anti-HER2 treatment)
Not yet recruiting
- Breast Cancer
- +2 more
- Cessation of anti-HER2 treatment
-
Boston, Massachusetts
- +1 more
Feb 9, 2023